New Antibody Cocktail Beats COVID‑19 Variants in the Lab
In a lab showdown between mice and hamsters, Washington University’s researchers proved that a two‑antibody cocktail can outclass a handful of the wildest SARS‑CoV‑2 mutants.
Why the cocktail matters
- The Alpha variant (UK), Beta (South Africa) and Gamma (Brazil) are already jaw‑dropping threats.
- An Indian strain resembling Delta was tossed in to see if the cocktail could handle anything that’s emerging.
- One‑shot treatments like Eli Lilly’s bamlanivimab fizzled when variants slipped sideways – so combo therapy was the real hope.
Getting down to the science
Scientists head‑to‑head the FDA‑approved treatments against the beefiest variants. They tossed in:
- Regeneron’s combo antibody set
- El Lilly’s two‑antibody blend
- Sotrovimab from Vir and G SK – a single‑shot that’s still on the radar
- AbbVie, Vir, and AstraZeneca’s still‑testing mixtures
Results? The combo shots stood firm even when one of the pair winked out. “Resistance popped up with some monotherapies, but never with combination therapy,” co‑author Jacco Boon told reporters.
What this means for the fight
With pathogens that keep remixing, a double‑dose strategy might just be the trick to keep emergency use approvals from slipping off the buffet. For now, the hamster bone‑crunching tests give a green light that two‑antibody cocktails could hold their own until the next pandemic hit.
